Chemotherapy for metastatic and recurrent cervical cancer

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 10, 2012, Pages

  Scatchard, Kate ^a   Forrest, Jennifer L ^b   Flubacher, Maxine ^c   Cornes, Paul ^d   Williams, Chris ^e  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CYTOTOXICITY; DRUG RESPONSE; FUNCTIONAL STATUS; HUMAN; INFECTION; KIDNEY DYSFUNCTION; METASTASIS; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; ADULT; AGE; AGED; FEMALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; UTERINE CERVIX TUMOR;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84871868141     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006469.pub2     Document Type: Review

References (60)

1. Alberts DS, Kronmal R, Baker LH, Stock-Novack DL, Surwit EA, Boutselis JG, et al.Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1987;5(11):1791-5. [PUBMED: 2445932]
2. Bezwoda WR, Nissenbaum M, Derman DP. Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate. Medical and Pediatric Oncology 1986;14(1):17-9. [PUBMED: 3512970]
3. Bloss JD, Blessing JA, Behrens BC, Mannel RS, Rader JS, Sood AK, et al.Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2002;20(7):1832-7. [PUBMED: 11919241]
4. Bond WH, Arthur K, Banks AJ, Freeman WE, Holme GM, Newsholme GA, et al.Combination chemotherapy in the treatment of advanced squamous cell carcinoma of the cervix. Clinical Oncology 1976;2(2):173-8. [PUBMED: 60188]
5. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1985;3(8):1079-85. [PUBMED: 3894589]
6. Cadron I, Jakobsen A, Vergote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer. Gynecologic and Obstetric Investigation 2005;59(3):126-9. [PUBMED: 15604591]
7. Edmonson JH, Johnson PS, Wieand HS, Malkasian GD, Cullinan SA, Brown LD, et al.Phase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma. American Journal of Clinical Oncology 1988;11(2):149-51. [PUBMED: 2451883]
8. Freedman RS, Herson J, Wharton JT, Rutledge FN. Single-agent chemotherapy for recurrent carcinoma of the cervix. Cancer Clinical Trials 1980;3(4):345-50. [PUBMED: 6775827]
9. Greenberg BR, Kardinal CG, Pajak TF, Bateman JR. Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treatment Reports 1977;61(7):1383-4. [PUBMED: 73417]
10. Lira-Puerto V, Silva A, Morris M, Martinez R, Groshen S, Morales-Canfield F, et al.Phase II trial of carboplatin or iproplatin in cervical cancer. Cancer Chemotherapy and Pharmacology 1991;28(5):391-6. [PUBMED: 1914084]
11. Brave M, Dagher R, Farrel A, Ramchandani R, Gobburu J, Booth R, et al.Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent or persistent cervical cancer. Oncology 2006;20:1401-16.
12. Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al.Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005;23(21):4626-33. [PUBMED: 15911865]
13. Monk BJ, Huang HQ, Cella D, Long HJ 3rd. Quality of life outcomes from a randomised phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2005;23(21):4617-25.
14. Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, et al.Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;100(3):537-43. [PUBMED: 16216315]
15. Malkasian GD Jr, Decker DG, Green SJ, Edmonson JH, Jefferies JA, Webb MJ. Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecologic Oncology 1981;11(2):235-9. [PUBMED: 7011913]
16. McGuire WP 3rd, Arseneau J, Blessing JA, DiSaia PJ, Hatch KD, Given FT Jr, et al.A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1989;7(10):1462-8. [PUBMED: 2674333]
17. Monk BJ. A randomised phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a GOG study. 01/06/2008.
18. McQuellon RP, Thaler HT, Cella D, Moore D. Quality of life outcomes from a randomised trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;101(2):296-304.
19. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al.Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2004;22(15):3113-9. [PUBMED: 15284262]
20. Moseley HS, Sasaki T, McConnell DB, Merhoff GC, Wilson WL, Grage TB, et al.A randomized pilot study comparing two regimens in the treatment of squamous cell carcinoma. Journal of Surgical Oncology 1976;8(1):35-42. [PUBMED: 55523]
21. Mountzios G, Dimpoulos MA, Bamias A, Vourli G, Kalofonos H, Aravantinos G, et al.Randomise multicentre phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Co-operative Oncology Group (HeCOG) study. Annals of Oncology 2009;20:1362-8.
22. Omura GA, Shingleton HM, Creasman WT, Blessing JA, Boronow RC. Chemotherapy of gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina, and vulva. Cancer Treatment Reports 1978;62(5):833-5. [PUBMED: 350400]
23. Omura GA, Velez-Garcia E, Birch R. Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix. Cancer Treatment Reports 1981;65(9-10):901-3. [PUBMED: 7196801]
24. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, et al.Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1997;15(1):165-71. [PUBMED: 8996138]
25. Palo GM, Bajetta E, Beretta G, Bonadonna G. Adriamycin plus bleomycin versus cyclophosphamide plus vincristine in advanced carcinoma of the uterine cervix. Tumori 1976;62(1):113-22. [PUBMED: 65039]
26. Pfeiffer P, Thomsen K, Bertelsen K. Teniposide or carboplatin in patients with recurrent or advanced cervical carcinoma. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 1997;7(2):1.
27. Thomsen TK, Pfeiffer P, Bertelsen K. Teniposide or carboplatin in patients with recurrent or advanced cervical carcinoma: a randomized phase II trial. International Journal of Gynecological Cancer 1998;8(4):310-14.
28. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecologic Oncology 1989;32(2):198-202. [PUBMED: 2910782]
29. Wallace HJ Jr, Hreshchyshyn MM, Wilbanks GD, Boronow RC, Fowler WC Jr, Blessing JA. Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix. Cancer Treatment Reports 1978;62(10):1435-41. [PUBMED: 709549]
30. Weiss G, Liu P, O'Sullivan J, Alberts D, Brown T, Neefe J, Hutchins L. A randomised phase II trial of trimetrexate or didemnin for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a SWOG trial. Gynecologic Oncology 1992;45:303-6.
31. Armstrong D, Blessing J, Rader J, Sorosky J. A randomised Phase II evaluation of bryostatin-1 in persistent or recurrent squamous cell carcinoma of the cervix: a Gynaecological Oncology Group study. Investigational New Drugs 2003;21(4):453-7.
32. Baker LH, Opipari MI, Wilson H, Bottomley R, Coltman CA Jr. Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer. Obstetrics and Gynecology 1978;52(2):146-50. [PUBMED: 79991]
33. Greggi S, D'Agostino G, Smaniotto D, Genovesi D, Lorusso D, Scambia G. Gemcitabine is ineffective in recurrent, preirradiated cervical cancer. Gynecologic Oncology 2000; Vol. 78, issue 1:76-7. [PUBMED: 10873416]
34. Kumar L, Pokharel YH, Kumar S, Singh R, Rath GK, Kochupillai V. Single agent versus combination chemotherapy in recurrent cervical cancer. The Journal of Obstetrics and Gynaecology Research 1998;24(6):401-9. [PUBMED: 10063235]
35. Saito I, Kitagawa R, Fukuda H, Shibata T, Katsumata N, Konishi I, et al.A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB persistent or recurrent cervical cancer: a Gynecologic Cancer Study group/Japan Clinical Oncology Group study (JCOG0505). Japanese Journal of Clinical Oncology 2010;40(1):90-3.
36. CTCAE . Common Terminology Criteria for Adverse Events V3.0, August 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 5 August 2012).
37. de la Motte Rouge T, Pautier P, Hamy AS, Duvillard P, Bruna A, Castaigne D, et al.Medical treatment of metastatic or recurrent cancer of the cervix. Bull Cancer 2006;93(3):263-70.
38. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
40. Eifel PJ, Berek JS, Thigpen JT. Gynaecological Cancers. Section 2. Cancer of the cervix, vagina, vulva. In: DeVita VT, Hellman S, Rosenberg SA editor(s). Cancer: Principles and Practice of Oncology. 6. Vol. 2, Philadelphia: Lippincott-Raven, 2001:1526-1556.
41. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al.EUROCARE-3: survival of cancer patients diagnosed 1990-94- results and commentary. Annals of Oncology 2003;14(Suppl 5):V61-118.
42. Ferlay J, Shin HR, Bray F, Forman D, Mathers C. Estimates of worldwide burden of cancer in 2008; GLOBOCAN. International Journal of Cancer 2010;127(12):2893-917.
43. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, et al.Concomitant chemotherapy and radiotherapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3.
44. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
45. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.Cancer statistics 2008. CA: A Cancer Journal for Clinicians 2008;58(2):71-96.
47. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. Journal of Clinical Oncology 2008;26(35):5802-12.
48. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. International Journal of Technology Assessment in Healthcare 2005;21(1):119-25.
49. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
50. Moore DH. Chemotherapy for recurrent cervical carcinoma. Current Opinions in Oncology 2006;18(5):516-9.
51. Moore K. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IV recurrent or persistent cervix cancer. Gynaecological Oncology 2007;105:299-303.
52. Mutch D, Bloss J. Gemcitabine in cervical cancer. Gynaecological Oncology 2003;90(2 part 2):S8-25.
53. National Cancer Institute. Cervical cancer, 2012. http://www.cancer.gov/cancertopics/types/cervical (accessed 5 August 2012).
54. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
55. Pectasides D, Kamposioras K, Papaxoinis D, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treatment Reviews 2008;34(7):603-13.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
57. Tewari KS, Monk BJ. Gynaecological group trials of chemotherapy for metastatic and recurrent cervical cancer. Current Oncology Reports 2005;7(6):419-34.
58. Tinker A, Bhagat K, Swenerton K, Hoskins P. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma; the BCCA experience. Gynaecological Oncology 2005;98(1):54-8.
59. Weiss GR, Green S, Hannigan EV, Boutselis JG, Surwit EA, Wallace DL, et al.A Phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix. A SWOG study. Gynaecological Oncology 1990;39(3):332-6.
60. Willmott LJ, Monk B. Cervical cancer therapy. Expert Review of Anticancer Therapy 2009;9(7):895-903.